Hong Kong's Frontage Holdings 9-month revenue rises 20.9%

Frontage Holdings

29/10/2026 08:43

Overview
Hong Kong drug development services firm's 9-month revenue rose 20.9% yr/yr to $231.4 mln
Net profit for 9 months more than doubled, up 113.1% yr/yr
Adjusted net profit rose 62.7% after excluding one-off and non-cash items

Outlook
Company did not provide specific guidance for future quarters or full year in its press release

Result Drivers
REVENUE GROWTH - 20.9% yr/yr revenue increase
PROFIT SURGE - Net profit more than doubled
ADJUSTED PROFIT RISE - Adjusted net profit rose 62.7% after excluding share-based compensation, amortisation, restructuring and M&A expenses

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
9M Revenue
 
$231.4 mln
 

Analyst Coverage
The current average analyst rating on the shares is "sell" and the breakdown of recommendations is no "strong buy" or "buy", no "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Frontage Holdings Corp is HK$1.12, about 25.2% below its October 28 closing price of HK$1.49
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 16 three months ago

Reuters Recommended Reads
Oct 27 - China's Hengrui Pharma nine-month profit rises on out-licensing gains
Oct 28 - Joinn Laboratories Q3 revenue rises on industry recovery

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)